ArticleFrontiers in immunology2016
Interleukin-27 Early Impacts
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Concomitant immunity in persistent Leishmania infections: could it represent an evolutionary balance and a vaccine target?Parasites & vectors · 2025Review
- MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.Frontiers in immunology · 2024Article
- Role of Cytokines in Experimental and Human Visceral Leishmaniasis.Frontiers in cellular and infection microbiology · 2021Review
- Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.The American journal of tropical medicine and hygiene · 2020Article
- Development of an Electrochemical Immunosensor for Specific Detection of Visceral Leishmaniasis Using Gold-Modified Screen-Printed Carbon Electrodes.Biosensors · 2020Article
- Interleukin-27 Functional Duality BalancesFrontiers in immunology · 2020Review
- Resistance to Experimental Visceral Leishmaniasis in Mice Infected WithFrontiers in immunology · 2020Article
- In vitro and in vivo immunomodulatory properties of octyl-β-D-galactofuranoside during Leishmania donovani infection.Parasites & vectors · 2019Article
- Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.Frontiers in immunology · 2019Review
- Understanding Resistance vs. Susceptibility in Visceral Leishmaniasis Using Mouse Models ofFrontiers in cellular and infection microbiology · 2019Article
- More than just exosomes: distinctJournal of extracellular vesicles · 2019Article
- Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.PLoS neglected tropical diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complexity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.